Rubius Therapeutics (RUBY) Stock Price, News & Analysis

Company Overview

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Key Stats

• Today's Range: $0.06 to $0.06
• 50-Day Range: $0.02 to $0.06
• 52-Week Range: $0.00 to $0.38
• Volume: 755,858 shs
• Average Volume: 1.15 million shs
• Market Capitalization: $5.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Rubius Therapeutics Stock Analysis - MarketRank™

Rubius Therapeutics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Rubius Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Rubius Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for RUBY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rubius Therapeutics does not currently pay a dividend.

Dividend Growth

Rubius Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.88

Short Interest

There is no current short interest data available for RUBY.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Rubius Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rubius Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.30% of the stock of Rubius Therapeutics is held by insiders.

RUBY Stock Analysis - Frequently Asked Questions

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) posted its earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.01.

When did Rubius Therapeutics IPO?

Rubius Therapeutics (RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What other stocks do shareholders of Rubius Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Biopharma (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX) and Tilray (TLRY).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 9/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RUBY
• CUSIP: N/A
• CIK: 1709401
• Web: www.rubiustx.com
• Phone: (508) 543-1720
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 90,480,000
• Free Float: 85,687,000
• Market Cap: $5.16 million
• Optionable: Not Optionable
• Beta: 2.59